The Outcomes of COVID-19 Patients with Spontaneous Intracerebral Hemorrhage Comorbidity and the Efficacy of Enoxaparin in Decreasing the Mortality Rate in Them: Single Egyptian Center Report

• Published in: Journal of personalized medicine 2022-11, Vol.12 (11), p.1822
• Main Authors: Shaban, Mohamed, Elgendy, Marwa O, Fahmy, Alzhraa M, Khalil, Doaa Mahmoud, El-Gendy, Ahmed O, Mahmoud, Tamer M, Abdelrahim, Mohamed E A
• Format: Article
• Language: English
• Subjects: Brain research; Comorbidity; Coronaviruses; COVID-19; Drug dosages; Edema; Glasgow Coma Scale; Guillain-Barre syndrome; Hematoma; Hemorrhage; Hypertension; Infections; Laboratories; Mortality; Neurosurgery; Oxygen therapy; Patients; Precision medicine; Severe acute respiratory syndrome coronavirus 2
• ISSN: 2075-4426; 2075-4426
• DOI: 10.3390/jpm12111822

Patients with neurological comorbidities are more likely to develop severe COVID-19. We aimed to detect the outcomes of COVID-19 patients with spontaneous intracerebral hemorrhage comorbidity and the role of enoxaparin in decreasing the mortality rate in these cases, even though enoxaparin is a potential cause of intracerebral hemorrhage. The patients were checked on to detect surveillance outcomes, the relationship between mortality and patient characteristics, and the relationship between enoxaparin and study outcomes. Chest condition and GCS improved in 67.9% of participants. Hematoma course increased in 49.1%. Midline-shift, brain-edema, and COVID symptoms improved in 67.9%. There was a non-significant difference in mortality regarding age and gender. There was a significant difference in mortality regarding treatment with enoxaparin; 75% of the patients who did not receive enoxaparin died. 92.6% of the patients who showed decreases in hematoma course were administered enoxaparin. 76.9% of the patients who showed increases in hematoma-course were administered enoxaparin. Most of the patients who were admitted to the neurosurgical unit with spontaneous intracerebral hemorrhage acquired the COVID-19 infection. Most of the cases included in this study did not progress to severe cases. The dying patients showed deterioration in both neurological and COVID-19 symptoms. The anticoagulant properties of enoxaparin given earlier before and throughout the infection can considerably reduce mortality in COVID-19 individuals with spontaneous intracerebral hemorrhage. It is recommended to use enoxaparin for cases with spontaneous intracerebral hemorrhage and COVID-19 regardless of hematoma size because the rate of improvement was greater than the mortality rate after using enoxaparin in this study.